Guidant Corporation Announces Exercise of Overallotment Option by Underwriters.INDIANAPOLIS--(BUSINESS WIRE)--December, 20, 1994--Guidant Corporation (NYSE NYSE See: New York Stock Exchange and PSE PSE 1. pale soft exudative pork. 2. portosystemic encephalopathy. : GDT) today announced that its U.S. underwriters, Morgan Stanley & Co., Incorporated; with Goldman, Sachs & Co.; Merrill Lynch & Co.; and J.P. Morgan Securities Inc., have exercised their option to purchase an additional 1.86 million shares of Guidant common stock to cover overallotments of Guidant's recent initial public offering. The international underwriters are Morgan Stanley & Co. International Limited; Goldman, Sachs International; Merrill Lynch International Limited; and J.P. Morgan Securities Ltd. Net proceeds to the company, including the initial offering of approximately $167.1 million, now total $192.5 million. Proceeds will be used to reduce outstanding debt and to repay debt incurred for the purchase of certain international assets from Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. . Guidant designs, develops, manufactures, and markets a broad range of products for use in cardiac rhythm management Cardiac rhythm management is a field of treatment in cardiology. The purpose is managing cardiac rhythm disorders. Usually it involves artificial pacemakers and/or implantable cardioverter-defibrillator therapy as well as antiarrhythmia drugs. and coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. intervention and other forms of minimally invasive surgery minimally invasive surgery Laparoscopic surgery, see there. See Laparoscopic cholecystectomy. . The registration statement related to this public offering was declared effective on Tuesday, December 13, by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A prospectus for the offering may be obtained from Morgan Stanley & Co., Incorporated, 1251 Avenue of the Americas, New York, New York 10020, Attention: Prospectus Mail Room, or by calling 212-703-4000. CONTACT: Guidant Corporate Communications David W. Pomfret, 317/276-6765 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion